Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Prior to his time at Pfizer, Dormitzer also spent many years at Novartis, eventually rising to the position of head of research for the flu vaccine division. "GSK has an industry-leading pipeline ...

The European Commission has just approved the prepandemic vaccine Prepandrix from GlaxoSmithKline ... application for its own prepandemic flu vaccine, Aflunov. The European Medicines Agency's ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing. Influenza causes 140,000 to ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator. Around the same time, a senior in Louisiana was diagnosed with the first ...

influenza, malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily.

BURLINGAME, CA, UNITED STATES, December 30, 2024 /EINPresswire / -- Influenza Vaccine market Analysis - 2024-2031: Coherent Market Insights has released a new report titled "Influenza Vaccine ...